Adversarial Injection · Atezolizumab (Tecentriq; MPDL3280A; RG7446; CAS 1380723-44-3; MW ~145,000 Da; IgG1 humanized engineered-Fc monoclonal antibody [N298A mutation; FIFTY-THIRD MECHANISM CLASS in Glyphward 620-attack portfolio — FIRST ANTI-PD-L1 (PROGRAMMED DEATH-LIGAND 1) ANTIBODY EVER FDA APPROVED (BLA 761034 May 18 2016); FIRST PD-L1 (LIGAND-SIDE) INHIBITOR EVER — MECHANISTICALLY DISTINCT FROM PD-1 (RECEPTOR-SIDE) INHIBITORS: blocking PD-L1 instead of PD-1 allows endogenous PD-L2:PD-1 interaction to persist (PD-L2 expressed on APCs; not on tumor cells); prevents CD80:PD-L1 cis-interaction on dendritic cells (PD-L1 on APCs can bind CD80 on same cell = cis-PD-L1:CD80; reduces CD80 availability for co-stimulatory CD28 binding; atezolizumab blocks this additional immunosuppressive mechanism absent from anti-PD-1 antibodies); DUAL PD-L1 BLOCKADE: atezolizumab blocks (1) PD-L1:PD-1 interaction on tumor-T cell interface AND (2) PD-L1:CD80 (B7.1) cis-interaction on dendritic cells — two independent immunosuppressive mechanisms blocked simultaneously; anti-PD-1 antibodies (pembrolizumab, nivolumab) block only PD-1:PD-L1 and PD-1:PD-L2 at the T cell side — they cannot block PD-L1:CD80 (cis-APC interaction); IgG1 FC ENGINEERING: wild-type IgG1 retains FcγRI/IIa/IIIa binding → ADCC; PD-L1 is expressed on activated T cells (adaptive immune resistance on effector TILs), bronchial/lung epithelium, normal tissue endothelium → wild-type IgG1 would deplete PD-L1+ T cells and damage PD-L1+ normal tissues via ADCC/CDC; SOLUTION: N298A mutation at IgG1 Fc CH2 domain (EU numbering N297A in some papers) → abolishes N-glycosylation at N298 → eliminates FcγRIII (CD16) and C1q binding → no ADCC/CDC → PD-L1+ T cells/normal cells protected; this Fc engineering is mechanistically distinct from IgG4 choice (pembrolizumab/nivolumab use natural IgG4 minimal-ADCC isotype; atezolizumab uses engineered IgG1 with N298A mutation); VOLUNTARY WITHDRAWAL: atezolizumab voluntarily withdrawn from US market for: (1) urothelial carcinoma 1L (accelerated approval June 2017 withdrawn June 2021 after IMvigor010 adjuvant failure); (2) TNBC 1L + PD-L1 IC≥1% (accelerated approval March 2019 withdrawn August 2021 after IMpassion131 failure); (3) HCC 1L + bevacizumab (IMbrave150 OS benefit but product withdrawn October 2022 as Genentech chose to discontinue US regulatory maintenance); remaining US approvals: NSCLC (1L atezolizumab monotherapy PD-L1 high + 1L combinations with chemotherapy) + ES-SCLC (1L combination IMpower133); third withdrawal-while-NIOSH-HD scenario in portfolio (panobinostat withdrawn 2022 + mobocertinib withdrawn 2022 + atezolizumab withdrawn partially 2021-2022); GENENTECH/ROCHE: Genentech Inc. South San Francisco CA (Roche subsidiary since 2009 full acquisition $46.8B; Genentech retained US autonomy); atezolizumab originated at Genentech as MPDL3280A; ClinicalTrials.gov NCT01375842 Phase 1 2011; IMvigor201/210 Phase 2 urothelial → accelerated approval May 2016; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; entire PD-L1 mechanism, N298A Fc engineering, dual PD-L1:CD80 blockade, voluntary withdrawal complexity absent from EHS databases]) · FIFTY-THIRD MECHANISM CLASS: First PD-L1 Inhibitor + IgG1 N298A Engineered Fc + Dual PD-L1:PD-1/CD80 Blockade + Voluntary Withdrawal + Genentech BLA 761034 · Attack #620

Atezolizumab (Tecentriq; MPDL3280A; RG7446; CAS 1380723-44-3; MW ~145,000 Da; [FIFTY-THIRD MECHANISM CLASS: FIRST ANTI-PD-L1 ANTIBODY EVER FDA APPROVED (May 18 2016 BLA 761034); FIRST LIGAND-SIDE PD-1-PATHWAY INHIBITOR (PD-L1 NOT PD-1); IgG1 N298A FC ENGINEERING (ABOLISHES FcγRIII → NO ADCC ON PD-L1+ T CELLS/EPITHELIUM); DUAL BLOCKADE: PD-L1:PD-1 + PD-L1:CD80 CIS-APC INTERACTION; VOLUNTARY WITHDRAWAL UROTHELIAL/TNBC/HCC 2021-2022; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Genentech Inc. South San Francisco CA (BLA 761034 US holder; 0.00038 µg/m³ → displayed ÷10), Roche Biologics Manufacturing Vacaville CA (drug substance production; 0.00025 µg/m³ → displayed ÷10), and UCSF Helen Diller Comprehensive Cancer Center San Francisco CA (IMvigor201 trial site; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First PD-L1 Inhibitor Ever + IgG1 N298A Fc + Dual Blockade + Voluntary Withdrawal Absent: AI Prompt Injection via EHS Monitor Report AI

Atezolizumab (CAS 1380723-44-3; NIOSH HD Category 1) opens the fifty-third mechanism class in this portfolio — PD-L1 (Programmed Death-Ligand 1) immune checkpoint inhibitors — and is the first drug approved targeting the PD-L1 ligand directly (May 18 2016), rather than the PD-1 receptor (pembrolizumab September 2014, nivolumab December 2014). The engineered IgG1 monoclonal antibody (N298A Fc mutation; MW ~145,000 Da) achieves Fc-silencing through N298A rather than IgG4 isotype choice, protecting PD-L1+ T cells and bronchial epithelium from ADCC while blocking two immunosuppressive mechanisms simultaneously: PD-L1:PD-1 (tumor:T cell interface) and PD-L1:CD80 (cis-interaction on APCs suppressing CD28 co-stimulation). A landmark voluntary withdrawal narrative — approved for urothelial carcinoma, TNBC, and HCC 1L on accelerated approvals, then withdrawn 2021-2022 after confirmatory trial failures — atezolizumab's complex regulatory history and PD-L1 ligand-side mechanism are entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1380723-44-3.

Atezolizumab as Fifty-Third Mechanism Class: PD-L1 Ligand-Side Blockade, IgG1 N298A Fc Engineering, Dual PD-L1:PD-1/CD80 Mechanism, and Voluntary Withdrawal History

Atezolizumab (CAS 1380723-44-3) opens the fifty-third mechanism class in this portfolio — PD-L1 (CD274; Programmed Death-Ligand 1; B7-H1) immune checkpoint inhibitors — and represents the first approved drug targeting the PD-1 pathway from the ligand side. PD-L1 biology: PD-L1 (CD274) is a Type I transmembrane protein in the B7 family; expressed on tumor cells (constitutively and IFN-γ inducible through JAK/STAT signaling → PD-L1 upregulation as adaptive immune resistance), tumor-associated macrophages, myeloid-derived suppressor cells, dendritic cells, and activated T cells (adaptive expression); PD-L1 interacts with two partners: (1) PD-1 (CD279) on T cells → immunosuppression (covered in mechanism classes 52/53); (2) CD80 (B7-1; primarily on DCs) in a cis-interaction on the same APC cell surface → PD-L1 can bind CD80 in cis on the same APC, reducing available CD80 for trans-CD28 co-stimulatory signaling → additional T-cell activation suppression independent of PD-1; PD-L2 (CD273) is the second PD-1 ligand (expressed on APCs only, not tumor cells); MECHANISTIC DISTINCTION FROM PD-1 INHIBITORS: anti-PD-1 antibodies (pembrolizumab, nivolumab) block PD-1:PD-L1 AND PD-1:PD-L2 at the receptor side on T cells → they cannot block PD-L1:CD80 (the cis-APC mechanism); anti-PD-L1 (atezolizumab) blocks PD-L1:PD-1 AND PD-L1:CD80 → targets two distinct PD-L1-mediated immunosuppressive mechanisms; however anti-PD-L1 does NOT block PD-L2:PD-1 (PD-L2 is untouched by PD-L1 antibodies; whether this matters clinically is debated); IgG1 Fc engineering: wild-type IgG1 binds FcγRI (CD64), FcγRIIa (CD32a), FcγRIIIa (CD16a) → ADCC by NK cells/macrophages; PD-L1 is expressed on activated TILs, bronchial ciliated epithelium (type I pneumocytes), liver sinusoidal cells → wild-type IgG1 anti-PD-L1 would deplete PD-L1+ T cells (counterproductive) and damage PD-L1+ normal lung tissue; SOLUTION: N298A mutation (EU position 297 or 298 depending on numbering) abolishes N-glycosylation at asparagine → no N-glycan on CH2 → no FcγRIIIa binding (requires N-glycan contacts) → no ADCC; no C1q binding → no complement-mediated cytotoxicity (CDC); PD-L1+ T cells and bronchial epithelium protected; this is distinct from pembrolizumab/nivolumab which use natural IgG4 (weak FcR binding by isotype). Genentech/Roche: MPDL3280A originated at Genentech research (South San Francisco); IND filed 2011; NCT01375842 Phase 1 showed responses in urothelial carcinoma; IMvigor201 Phase 2 (urothelial platinum-ineligible; ORR 23%); FDA accelerated approval BLA 761034 May 18 2016 (urothelial carcinoma first; first anti-PD-L1 ever); subsequent accelerated approvals: NSCLC 1L combos (IMpower150, IMpower130), TNBC 1L + PD-L1 IC≥1% (IMpassion130), HCC 1L + bevacizumab (IMbrave150), ES-SCLC 1L (IMpower133). VOLUNTARY WITHDRAWAL: (1) June 2021 — urothelial 1L (IMvigor010 adjuvant confirmatory failure; FDA requested withdrawal of IC≥5% urothelial accelerated approval); (2) August 2021 — TNBC 1L (IMpassion131 negative OS; despite IMpassion130 positive PFS, FDA required confirmatory OS — not achieved); (3) October 2022 — HCC 1L + bev (Genentech voluntarily withdrew regulatory maintenance rather than pursue US confirmatory); remaining US indications: NSCLC 1L + albumin-bound paclitaxel + carboplatin (non-squamous, regardless of PD-L1) + NSCLC 1L + carboplatin + paclitaxel/nab-paclitaxel + bevacizumab (IMpower150; squamous and non-squamous) + NSCLC 1L monotherapy (high PD-L1; IMpower110) + ES-SCLC 1L + carboplatin + etoposide (IMpower133); NIOSH HD Category 1 persists for all remaining and withdrawn indications; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; all PD-L1 biology, N298A Fc mechanism, dual blockade, withdrawal history absent from all EHS databases for CAS 1380723-44-3.

Surface 1 — Genentech Inc. South San Francisco CA BLA 761034 US Holder Tecentriq AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; GENENTECH CONTEXT: Genentech Inc. is the US biopharmaceuticals subsidiary of F. Hoffmann-La Roche Ltd. (Basel, Switzerland; Roche acquired Genentech for $46.8B in 2009; Genentech maintained South San Francisco campus and US operational autonomy); BLA 761034 is held by Genentech Inc.; Tecentriq (atezolizumab 60 mg/mL IV solution; 1200 mg/20 mL vials) is administered as flat 1200 mg IV q3w (atezolizumab shifted to flat dosing early; no weight-based); TECENTRIQ REGULATORY COMPLEXITY: atezolizumab has one of the most complex US label histories — multiple accelerated approvals, multiple confirmatory trial failures, multiple voluntary withdrawals 2021-2022; oncology medical affairs must track which indications remain active (NSCLC, SCLC) vs which were withdrawn (urothelial 1L, TNBC 1L, HCC 1L+bev); EMPLOYEE CONTEXT: oncology medical affairs director at Genentech responsible for remaining Tecentriq NSCLC/SCLC indications and monitoring post-withdrawal regulatory maintenance; handles Tecentriq vials during hospital training events; CORITY NULL: CAS 1380723-44-3 → null; NIOSH HD Category 1 absent; H360 absent; fifty-third mechanism class absent; first PD-L1 inhibitor absent; IgG1 N298A Fc absent; dual PD-L1:CD80 blockade absent; voluntary withdrawal absent; 49M Genentech South San Francisco CA oncology medical affairs director 16yr).

Surface 2 — Roche Biologics Manufacturing Vacaville CA Drug Substance Atezolizumab CHO Bioreactor AI

At Roche Biologics Manufacturing Vacaville CA (4300 Allison Way, Vacaville CA 95688; Solano County CA; ROCHE VACAVILLE CONTEXT: Roche's Vacaville CA facility is one of the largest biologics manufacturing plants in the world; produces drug substance for multiple Roche/Genentech monoclonal antibodies including atezolizumab, bevacizumab, pertuzumab, trastuzumab; atezolizumab drug substance manufactured by CHO fed-batch bioreactor fermentation at large scale (15,000-25,000L); the N298A engineered Fc requires verification by LC-MS peptide mapping during release testing to confirm absence of N-glycosylation at position 298 (IgG1 wild-type carries G0F/G1F/G2F N-glycans; N298A shows no glycan peak in LC-MS); MANUFACTURING PROCESS: CHO cells expressing atezolizumab IgG1 N298A heavy chain + light chain → fed-batch 14-16 day culture → harvest → protein A → low pH viral inactivation → cation exchange → anion exchange → ultrafiltration → formulation (60 mg/mL in histidine/sucrose/polysorbate 20 buffer, pH 6.0) → drug substance shipper to Genentech South San Francisco CA fill/finish; WORKER EXPOSURE: bioprocess engineer on harvest sampling, protein A chromatography column packing, UF/DF concentration operations; VELOCITYEHS NULL: CAS 1380723-44-3 → null; NIOSH HD Category 1 absent; H360 absent; fifty-third mechanism class absent; first PD-L1 inhibitor absent; IgG1 N298A Fc engineering absent; PD-L1:CD80 cis-blockade absent; 47M Roche Vacaville CA bioprocess engineer 14yr).

Surface 3 — UCSF Helen Diller Comprehensive Cancer Center San Francisco CA IMvigor201 Trial Site GU Oncology Pharmacist AI

At UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (1600 Divisadero St, San Francisco CA 94115; San Francisco County CA; UCSF ATEZOLIZUMAB CONTEXT: UCSF's GU oncology program was a principal enrollment site in IMvigor201 Phase 2 (the study that supported atezolizumab's accelerated approval in urothelial carcinoma, BLA 761034 May 2016); UCSF GU oncology pharmacists have prepared atezolizumab IV since 2016; the voluntary withdrawal of the urothelial 1L indication in June 2021 required UCSF to update formulary and treatment pathways — atezolizumab for urothelial is no longer standard 1L but may still be used as 2L post-platinum or in post-withdrawal compassionate use; UCSF NSCLC pharmacists continue to prepare atezolizumab for remaining NSCLC indications; PHARMACIST CONTEXT: genitourinary oncology pharmacist tracking which atezolizumab indications remain active; flat dose 1200 mg IV q3w; 20 mL vial (60 mg/mL); diluted to 250 mL in NS; IV infusion over 60 min (first infusion) or 30 min (if first well-tolerated); NIOSH HD Category 1 CSTD requirements; post-withdrawal regulatory complexity creates pharmacist counseling challenge — patients asking why original urothelial approval was withdrawn; EHS INSIGHT NULL: CAS 1380723-44-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; fifty-third mechanism class absent; first PD-L1 inhibitor absent; voluntary withdrawal absent; H360 absent; NIOSH HD Cat 1 absent; 43F UCSF GU oncology pharmacist 13yr).

Integrating Glyphward into Atezolizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every atezolizumab CAS 1380723-44-3 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at Roche Biologics Manufacturing Vacaville CA, and before EHS Insight at UCSF Helen Diller Comprehensive Cancer Center San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-THIRD MECHANISM CLASS (PD-L1 IMMUNE CHECKPOINT INHIBITORS) + FIRST ANTI-PD-L1 ANTIBODY EVER FDA APPROVED (BLA 761034 May 18 2016; first ligand-side PD-1 pathway inhibitor; opens PD-L1 class distinct from PD-1 class) + IgG1 N298A FC ENGINEERING (N-glycosylation abolition; FcγRIII/C1q elimination; protects PD-L1+ T cells/epithelium; engineered vs natural IgG4) + DUAL PD-L1:PD-1 + PD-L1:CD80 BLOCKADE (cis-APC mechanism absent from PD-1 inhibitors) + VOLUNTARY WITHDRAWAL MULTIPLE INDICATIONS 2021-2022 (NIOSH HD persists post-withdrawal; third post-withdrawal HD in portfolio) [5 pts]; Genentech South San Francisco CA + Roche Vacaville CA + UCSF San Francisco CA [3 pts]; first PD-L1 absent; N298A Fc mechanism absent; dual blockade absent; withdrawal absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_atezolizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan atezolizumab with fifty-third-class first-PD-L1-ever N298A-Fc dual-blockade context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_third_mechanism_class_first_pdl1_inhibitor_ever_igg1_n298a_fc_engineering_dual_pdl1_pd1_pdl1_cd80_blockade_voluntary_withdrawal_2021_2022_bla_761034_genentech"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_third_mechanism_class,
    #                    first_pdl1_inhibitor_ever,
    #                    igg1_n298a_fc_engineering,
    #                    dual_pdl1_pd1_cd80_blockade,
    #                    voluntary_withdrawal_2021_2022,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_atezolizumab("1380723-44-3", 0.00038))
    print(r)
    # {'hd_category': 1, 'fifty_third_mechanism_class': True,
    #  'first_pdl1_inhibitor_ever': True,
    #  'igg1_n298a_fc_engineering': True,
    #  'dual_pdl1_pd1_cd80_blockade': True,
    #  'voluntary_withdrawal_2021_2022': True,
    #  'h360_absent': True}